$1.06
10.41% today
Nasdaq, Apr 02, 10:00 pm CET
ISIN
US91381U1016
Symbol
UBX
Sector
Industry

Unity Biotechnology, Inc. Stock price

$0.96
-0.59 38.06% 1M
-0.48 33.33% 6M
-0.02 1.67% YTD
-0.70 42.16% 1Y
-11.24 92.13% 3Y
-51.84 98.18% 5Y
-165.54 99.42% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.08 7.68%
ISIN
US91381U1016
Symbol
UBX
Sector
Industry

Key metrics

Market capitalization $16.19m
Enterprise Value $16.50m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.49
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-32.23m
Free Cash Flow (TTM) Free Cash Flow $-20.87m
Cash position $23.23m
EPS (TTM) EPS $-1.54
P/E forward negative
P/S forward 40.48
EV/Sales forward 41.25
Short interest 3.83%
Show more

Is Unity Biotechnology, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Unity Biotechnology, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Unity Biotechnology, Inc. forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Unity Biotechnology, Inc. forecast:

Buy
100%

Financial data from Unity Biotechnology, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.87 0.87
26% 26%
-
-0.87 -0.87
26% 26%
-
- Selling and Administrative Expenses 15 15
2% 2%
-
- Research and Development Expense 15 15
16% 16%
-
-31 -31
8% 8%
-
- Depreciation and Amortization 0.87 0.87
26% 26%
-
EBIT (Operating Income) EBIT -32 -32
9% 9%
-
Net Profit -26 -26
39% 39%
-

In millions USD.

Don't miss a Thing! We will send you all news about Unity Biotechnology, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Unity Biotechnology, Inc. Stock News

Neutral
GlobeNewsWire
9 days ago
Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidence interval), but did not meet statistical non-inferiority on the average of weeks 20 and 24, the primary analysis endpoint (met at 88% confidence interval) UBX1325-treated patients had a +5.2 lette...
Neutral
GlobeNewsWire
10 days ago
SOUTH SAN FRANCISCO, Calif., March 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host a virtual investor event on Monday, March 24, 2025, at 8:00 AM ET. To register, click here .
Neutral
GlobeNewsWire
26 days ago
SAN FRANCISCO, March 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 31, 2024.
More Unity Biotechnology, Inc. News

Company Profile

Unity Biotechnology, Inc. operates as a biotechnology company engaged in the research and development of therapeutics to extend the human health span. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi and Daohong Zhou on March 30, 2009 and is headquartered in Brisbane, CA.

Head office United States
CEO Anirvan Ghosh
Employees 16
Founded 2009
Website www.unitybiotechnology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today